Physician profile
Michael D Gordon
NPI 1013905629
$3,478.82
in general payments reported to CMS, 2019-2025
29 companies · $564 in 2025
The $564 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,601 · 2020: $168 · 2021: $46.07 · 2022: $280 · 2023: $475 · 2024: $344 · 2025: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,383.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tosoh Bioscience, INC. | $958.00 | 2019 | |
| Novo Nordisk INC | $374.65 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $272.86 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $239.43 | 2019-2025 | Jardiance, Synjardy |
| Coastal Medical Technologies LLC | $159.98 | 2023 | |
| Astellas Pharma US INC | $156.60 | 2019-2025 | Veozah |
| Boston Scientific Corporation | $155.95 | 2019-2025 | Obsidio, Embold Fibered |
| Phathom Pharmaceuticals, INC. | $152.42 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $121.71 | 2019-2025 | |
| Argon Medical Devices, INC. | $91.32 | 2023-2025 | Cleaner, Clot Management |
| Abbott Laboratories | $84.73 | 2019 | |
| Pfizer INC. | $80.87 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $80.46 | 2019-2020 | |
| Glaxosmithkline, LLC. | $76.19 | 2020-2023 | Trelegy Ellipta |
| Amgen INC. | $74.34 | 2021-2025 | Repatha, Otezla |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $65.44 | 2019-2024 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $58.00 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $43.35 | 2019-2023 | Livalo, Seglentis |
| Exact Sciences Corporation | $42.15 | 2023 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $38.23 | 2019 | |
| Inspire Medical Systems, INC. | $32.62 | 2025 | Inspire |
| Phadia US INC. | $18.44 | 2025 | Immunocap |
| Sanofi-Aventis U.S. LLC | $17.97 | 2019 | |
| Allergan, INC. | $17.94 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.98 | 2021 | |
| Aytu Biopharma, INC. | $14.47 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.23 | 2023 | Xifaxan |
| Ferring Pharmaceuticals INC. | $14.18 | 2020 | |
| Currax Pharmaceuticals LLC | $5.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.